Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02765633 · ClinicalTrials.gov registry record · Phase 1

Cangrelor Neonatal PK/PD and Safety Study

A Phase 1 study, sponsored by Chiesi Farmaceutici S.p.A..

Completed
Registry status
Phase 1
Development phase
22
Enrollment target

NCT02765633 is a Phase 1 study that has completed, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 22 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02765633, a Phase 1 study, has completed, sponsored by Chiesi Farmaceutici S.p.A..

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target

Study Summary

The purpose of this study is to assess the PK/PD and safety profile of cangrelor in neonatal participants at risk of thrombosis.

Interventions

  • DRUG Cangrelor

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2017-01-03
Est. Completion 2019-12-23
Phase Phase 1

Sponsor

Chiesi Farmaceutici S.p.A.

30 total trials

What the Registry Record Tells You About NCT02765633

The ClinicalTrials.gov registry entry for NCT02765633 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chiesi Farmaceutici S.p.A., which has 30 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Cangrelor is the first listed.

NCT02765633 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02765633 about?

NCT02765633 is a clinical study titled "Cangrelor Neonatal PK/PD and Safety Study". The purpose of this study is to assess the PK/PD and safety profile of cangrelor in neonatal participants at risk of thrombosis.

What is the current status of trial NCT02765633?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2017-01-03. Estimated completion is 2019-12-23.

What interventions are being tested in trial NCT02765633?

The interventions under investigation include: Cangrelor (DRUG).

Who is sponsoring clinical trial NCT02765633?

This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.